A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of RV1729 for up to 28 Days
Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
RV1729 is a new medicine being developed for the potential treatment of asthma and smoking
related lung disease (also known as chronic obstructive pulmonary disease - COPD).
The objective of this study is to investigate the safety, tolerability and pharmacokinetics
of single doses of RV1729 and repeat doses of RV1729 for up to 28 days.